Antibiotic Market Snapshot: In Exchange For Higher Prices, More Value
Executive Summary
Drug developers face enormous regulatory and commercial hurdles in the antibiotics market, but industry is looking to challenge the current business model with new premium-priced drugs that deliver compelling pharmaco-economic benefits over generics.
You may also be interested in...
AstraZeneca Sells Small-Molecule Antibiotics To Pfizer But Still Investing In R&D
AstraZeneca is selling its late-stage small molecule antibiotics business to Pfizer in a deal that could reach more than $1.5bn, but the company – one of just a few big pharmas working in antibiotics R&D – says it will continue to study novel antibiotics via its MedImmune biologics division.
AstraZeneca Will Establish Antibiotic Subsidiary With $40 Million
The big pharma – one of the few still investing in antibiotic research – will create a stand-alone subsidiary to focus exclusively on early-stage antibiotic development.
Under Pressure: Can Merck Show Cubist Is Worth $9.5 Billion Without Cubicin?
Hours after Merck revealed a merger agreement with Cubist, a court ruled that generic versions of Cubist’s big seller Cubicin can launch in 2016, two years earlier than expected, putting the pressure on Merck to justify the pricey acquisition.